The ClinicalTrials.gov record for AGLOW (NCT07161037) was updated in August 2026 to active, not recruiting, with 26 participants enrolled against an initial target of 24. The Phase 2a study began in November 2025 and now has a primary completion estimate of July 2027.
VX-407 is Vertex's oral candidate for ADPKD patients carrying a specific subset of PKD1 variants. The approach mirrors the company's playbook in cystic fibrosis, where CFTR modulators correct the function of specific mutant proteins rather than treating downstream symptoms. If it works in PKD, it would be the first genotype-targeted therapy for the disease — but by design it would apply only to patients with qualifying variants.
The trial is small and enrollment closed quickly, which is typical of a variant-restricted proof-of-concept study. For patients, the relevant point is that genetic testing determines eligibility for this class of therapy; knowing your specific PKD1 variant is becoming practically useful rather than merely academic.
Vertex completed a 159-participant Phase 1 program before this study. With enrollment closed, initial data would be the next milestone.